The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer.
Büscheck F, Zub M, Heumann A, Hube-Magg C, Simon R, Lang DS, Höflmayer D, Neubauer E, Jacobsen F, Hinsch A, Luebke AM, Tsourlakis MC, Sauter G, Huland H, Graefen M, Haese A, Heinzer H, Schlomm T, Clauditz TS, Burandt E, Wilczak W, Steurer S, Minner S.
Büscheck F, et al. Among authors: schlomm t.
Tumour Biol. 2019 Jul;41(7):1010428318824815. doi: 10.1177/1010428318824815.
Tumour Biol. 2019.
PMID: 31296150
Free article.